Experience of robot-assisted radical prostatectomy after hemiablation of the prostate with high-intensity focused ultrasound using the Focal One robotic platform: clinical case

Cover Page

Cite item

Full Text

Abstract

As new methods of focal treatment become more and more popular in the treatment of prostate cancer, cases of ineffective treatment are gradually revealed, which require correction in the volume of surgical or other method of treatment.

The article describes experience of radical treatment of prostate cancer in case of local recurrence of the disease after ultrasound ablation of the prostate.

A 58-year-old man who 1 year ago had undergone high-intensity focused ultrasound (HIFU) hemiablation of the left prostatic lobe using Focal One robotic platrform due to prostate adenocarcinoma was examined 1 year after the operation. Total prostate-specific antigen blood level was 5.45 ng/mL. The patient underwent a control transrectal biopsy of the prostate from 12 cores, which revealed recurrence of the disease in the contralateral (previously untreated) prostate lobe. The patient underwent robot-assisted radical prostatectomy. Operative time was 80 minutes. The patient was discharged from the hospital on the 7th day with no postoperative complications. The urethral catheter was removed on the 6th day after control CT cystography. Erectile function and urine retention were preserved. Total prostate-specific antigen level after 6 months of follow-up did not exceed 0.02 ng/mL.

Robot-assisted radical prostatectomy is an effective and safe method of treatment in patients with recurrent prostatic adenocarcinoma after HIFU if performed by a surgeon with sufficient experience in robot-assisted surgery.

About the authors

A. I. Alaverdyan

Russian University of Medicine, Ministry of Health of Russia;
Moscow Urological Center, Botkin Hospital, Moscow Healthcare Department

Author for correspondence.
Email: dr.alaverdyan@mail.ru
ORCID iD: 0000-0002-6369-7699

Artem I. Alaverdyan 

Build. 1, 20 Delegatskaya St., Moscow 127473,

Build. 20, 5 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

A. V. Govorov

Russian University of Medicine, Ministry of Health of Russia;
Moscow Urological Center, Botkin Hospital, Moscow Healthcare Department

ORCID iD: 0000-0003-3299-0574

Build. 1, 20 Delegatskaya St., Moscow 127473,

Build. 20, 5 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

A. О. Vasilyev

Russian University of Medicine, Ministry of Health of Russia;
Moscow Urological Center, Botkin Hospital, Moscow Healthcare Department;
Research Institute of Healthcare Organization and Medical Management, Moscow Healthcare Department

ORCID iD: 0000-0001-5468-0011

Build. 1, 20 Delegatskaya St., Moscow 127473,

Build. 20, 5 2nd Botkinskiy Proezd, Moscow 125284,

9 Sharikopodshipnikovskaya St., Moscow 115088

Russian Federation

K. B. Kolontarev

Russian University of Medicine, Ministry of Health of Russia;
Moscow Urological Center, Botkin Hospital, Moscow Healthcare Department

ORCID iD: 0000-0003-4511-5998

Build. 1, 20 Delegatskaya St., Moscow 127473,

Build. 20, 5 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

E. A. Prilepskaya

Moscow Urological Center, Botkin Hospital, Moscow Healthcare Department

ORCID iD: 0000-0003-4599-6094

Build. 20, 5 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

D. Yu. Pushkar

Russian University of Medicine, Ministry of Health of Russia;
Moscow Urological Center, Botkin Hospital, Moscow Healthcare Department

ORCID iD: 0000-0002-6096-5723

Build. 1, 20 Delegatskaya St., Moscow 127473,

Build. 20, 5 2nd Botkinskiy Proezd, Moscow 125284

Russian Federation

References

  1. State of oncological care in Russia in 2021. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 239 p. (In Russ.).
  2. Ahmed H.U., Akin O., Coleman J.A. et al. Transatlantic consensus group on active surveillance and focal therapy for prostate cancer. BJU Int 2012;109(11):1636–47. doi: 10.1111/j.1464-410X.2011.10633.x
  3. Vasilyev A.V., Govorov A.V., Shiryaev A.A. et al. Focal therapy of prostate cancer: patient selection, current limitations, and perspective of introduction into clinical practice. Onkourologiya = Cancer Urology 2017; 13(4):55–63. (In Russ.). doi: 10.17650/1726-9776-2017-13-4-55-63
  4. Levin V.P. Clinical, morphological and immunohistochemical characteristics of prostatic adenocarcinoma in the context of HIFU therapy. Dis. … candidate of medical sciences. Novosibirsk, 2019. (In Russ.).
  5. Chaussy C.G., Thuroff S.F. Robotic high-intensity focusedultrasound for prostate cancer: what have we learned in 15 years of clinical use? Curr Urol Rep 2011;12(3):180–7. doi: 10.1007/s11934-011-0184-2
  6. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022.
  7. Pushkar D.Yu., Govorov A.V., Vasiliev A.O. et al. Implementation of the Moscow program of prostate cancer early diagnosis and treatment. Proceedings of the Scientific Research Institute of Healthcare Organization and Medical Management. Collection of research articles. V. 5. Moscow: Gosudarstvennoe budzhetnoe uchrezhdenie goroda Moskvy “Nauchno-issledovatelskiy institut organizatsii zdravookhraneniya i meditsinskogo menedzhmenta Departamenta zdravookhraneniya goroda Moskvy”, 2020. 128 p. (In Russ.).
  8. Mearini L., D’Urso L., Collura D. et al. High-intensity focused ultrasound for the treatment of prostate cancer: a prospective trial with long-term follow-up. Scand J Urol 2015;49(4):267–74. doi: 10.3109/21681805.2014.988174

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2023



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36986 от  21.07.2009.